New Peptide Technology Against Cancer bags 25 Million Euros

15/10/2014 - 3 minutes

Bicycle Therapeutics, a next generation biotherapeutics UK-based company developing first-in-class bicyclic peptides, announced that it had secured an equity financing of €25 million for the clinical development of therapeutic bicycle drug candidates in oncology. 

Bicycle has used its proprietary bicyclic peptide technology that enables to discover a new class of drug candidates, which have similar selectivity and potency to antibodies but are 100-fold smaller and are manufactured using simple, economic chemical synthesis. This financing will support the clinical development of bicycle-drug conjugates (BDCs) that are highly selective to tumour-specific targets, with sub-nanomolar affinities. Preclinical models show that these BDCs extravasate and penetrate tissues much more rapidly and efficiently than antibodies, effecting rapid cell killing through the tumour mass and fast clearance. This results in effective tumour lysis with minimal systemic exposure.

You can have a look on this video. The models are the molecular dynamics of the same amino acid sequence as a linear peptide (left), as a monocycle (centre) and as a bicycle (right). The higher constraint of the bicycle results in the three side chains being more frequently in the correct orientation to bind with the target.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: